Summit Therapeutics SMMT Gross Unrealized Gains
Gross Unrealized Gains at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's gross unrealized gains.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Summit Therapeutics's gross unrealized gains?
- Summit Therapeutics (SMMT) reported gross unrealized gains of $0 in Q1 2026.
- What is the long-term trend for Summit Therapeutics's gross unrealized gains?
- Over 2 years (2023 to 2025), Summit Therapeutics's gross unrealized gains has grown at a 118.6% compound annual growth rate (CAGR), from $36K to $172K.